Ward T - Search Results

1

Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C.

McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. McEwan P, et al. Among authors: ward t. PLoS One. 2015 Jan 30;10(1):e0117334. doi: 10.1371/journal.pone.0117334. eCollection 2015. PLoS One. 2015. PMID: 25635922 Free PMC article.

2

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.

McEwan P, Ward T, Yuan Y, Kim R, L'italien G. McEwan P, et al. Among authors: ward t. Hepatology. 2013 Jul;58(1):54-64. doi: 10.1002/hep.26304. Epub 2013 May 27. Hepatology. 2013. PMID: 23389841

3

Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.

McEwan P, Bennett H, Ward T, Bergenheim K. McEwan P, et al. Among authors: ward t. Pharmacoeconomics. 2015 Feb;33(2):149-61. doi: 10.1007/s40273-014-0225-z. Pharmacoeconomics. 2015. PMID: 25344660

4

Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration.

McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. McEwan P, et al. Among authors: ward t. Med Decis Making. 2015 Jul;35(5):660-70. doi: 10.1177/0272989X14565821. Epub 2015 Jan 16. Med Decis Making. 2015. PMID: 25596535

5

Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre.

Selvapatt N, Ward T, Bailey H, Bennett H, Thorne C, See LM, Tudor-Williams G, Thursz M, McEwan P, Brown A. Selvapatt N, et al. Among authors: ward t. J Hepatol. 2015 Oct;63(4):797-804. doi: 10.1016/j.jhep.2015.05.015. Epub 2015 May 27. J Hepatol. 2015. PMID: 26024832

6

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model.

McEwan P, Ward T, Bennett H, Bergenheim K. McEwan P, et al. Among authors: ward t. Cost Eff Resour Alloc. 2015 Aug 4;13:12. doi: 10.1186/s12962-015-0038-8. eCollection 2015. Cost Eff Resour Alloc. 2015. PMID: 26244041 Free PMC article.

7

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.

McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H. McEwan P, et al. Among authors: ward t. Hepatol Res. 2016 Mar;46(5):423-33. doi: 10.1111/hepr.12570. Epub 2015 Oct 6. Hepatol Res. 2016. PMID: 26440999

8

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.

McEwan P, Bennett H, Ward T, Webster S, Gordon J, Kalsekar A, Yuan Y, Brenner M. McEwan P, et al. Among authors: ward t. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):173-80. doi: 10.1097/MEG.0000000000000510. Eur J Gastroenterol Hepatol. 2016. PMID: 26545086

9

Comparing the Use of Patient-Level Data to An Average Patient Profile Within a Type 2 Diabetes Simulation Model.

McEwan P, Bennett H, Ward T, Bergenheim K. McEwan P, et al. Among authors: ward t. Value Health. 2014 Nov;17(7):A546. doi: 10.1016/j.jval.2014.08.1768. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201770 Free article. No abstract available.

10

Modelling the Relationship between Sustained Virologic Response and Treatment Uptake Rates on Future Prevalence and Incidence of Hepatitis C in the UK.

Bennett H, McEwan P, Ward T, Kalsekar A, Yuan Y. Bennett H, et al. Among authors: ward t. Value Health. 2014 Nov;17(7):A682. doi: 10.1016/j.jval.2014.08.2547. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202526 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,873 results

Search Page

Filters